IPHA
Strong SellHot AirInnate Pharma S.A. · Healthcare · France · $248M · Avg Vol: $579K/d
Hot Air: Rising on momentum alone: weak business, rich price.
16
StockRankGet insider-trade alerts
QualityQuality
10
ValueValue
24
MomentumMomentum
62
P/E (TTM)
—
peers 22.9x
ROE
—
peers -34.6%
D/E
—
peers 0.4x
Dividend %
—
trailing yield
ABOUT INNATE PHARMA S.A.
Read
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 57.0M | 59.6M | 14.5M | 3.2M | -61.7% | 10.3M |
| EPS | -0.84 | -0.10 | -0.70 | -0.63 | — | -0.59 |
| Shares | 79.5M | 80.8M | 83.8M | 93.7M | +17.8% | 111.7M |
| Debt | 48.5M | 45.8M | 35.6M | 25.9M | -18.9% | 25.9M |
| Equity | 62.2M | 59.6M | 10.2M | -24.9M | -59.6% | — |
| Op CF | -22.0M | -60.6M | -7.9M | -37.4M | — | -60.6M |
| Inv CF | 2.2M | 8.4M | 10.6M | 23.7M | — | — |
| Fin CF | -2.1M | 7.0M | -6.9M | -2.3M | — | — |
Loading 1Y...
PRICE (1Y)+9.8%
SMA 50SMA 200
Close
$1.90
RSI (14)
28.4
52W High
$2.71
From 52W High
0.7%
SCORE BREAKDOWN
Quality
10
ROIC
-186.9%3.3
ROE
—N/A
GP/Assets
-55.2%1.1
Op. Margin
-689.6%8.5
FCF/Assets
-55.7%5.9
Piotroski
12.4
Int. Cover
-50.0x5.9
D/E Ratio
—N/A
Current Ratio
1.27x19.3
Value
24
P/E (TTM)
—N/A
EV/EBITDA
-2.9x25.0
P/FCF
—N/A
P/B
-6.2x25.0
P/S
20.5x15.0
Div Yield
—N/A
Momentum
62
52W High %
70%50.6
RS 6M
33%84.9
SMA 50/200
1.13x80.6
EPS Rev 4W
+31.5%97.3
EPS Rev 12W
—N/A
EPS Improve
+8%26.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$248M
P/E (Forward)
-3.5x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IPHA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IPHA | Innate Pharma S.A.(you) | $248M | 16 | Strong Sell |
| TNG.PA | Transgene SA | $259M | 18 | Strong Sell |
| CLLS | Cellectis S.A. | $342M | 6 | Strong Sell |
| ALSEN.PA | Sensorion SA | $162M | 3 | Strong Sell |
| VALN | Valneva SE | $610M | 12 | Strong Sell |
| 0QAV.L | Nanobiotix S.A. | $627M | 5 | Strong Sell |
| ALTHX.PA | THX Pharma Société Anonyme | $71M | 9 | Strong Sell |
| OSE.PA | OSE Immunotherapeutics SA | $89M | 4 | Strong Sell |
| ALGAE.PA | Fermentalg SA | $64M | 21 | Sell |
| ABNX.PA | ABIONYX Pharma SA | $100M | 1 | Strong Sell |
Peer medians: ROE -34.6% · P/E 22.9x · Gross margin 72.6%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.